204 related articles for article (PubMed ID: 27139631)
1. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Chen H; Tucker J; Wang X; Gavine PR; Phillips C; Augustin MA; Schreiner P; Steinbacher S; Preston M; Ogg D
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):682-93. PubMed ID: 27139631
[TBL] [Abstract][Full Text] [Related]
2. X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor.
Elkins JM; Wang J; Deng X; Pattison MJ; Arthur JS; Erazo T; Gomez N; Lizcano JM; Gray NS; Knapp S
J Med Chem; 2013 Jun; 56(11):4413-21. PubMed ID: 23656407
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
5. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
[TBL] [Abstract][Full Text] [Related]
6. Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity.
Kedika SR; Shukla SP; Udugamasooriya DG
Bioorg Med Chem Lett; 2020 Dec; 30(23):127552. PubMed ID: 32946922
[TBL] [Abstract][Full Text] [Related]
7. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
[TBL] [Abstract][Full Text] [Related]
8. Detection of allosteric kinase inhibitors by displacement of active site probes.
Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Nguyen D; Lemos C; Wortmann L; Eis K; Holton SJ; Boemer U; Moosmayer D; Eberspaecher U; Weiske J; Lechner C; Prechtl S; Suelzle D; Siegel F; Prinz F; Lesche R; Nicke B; Nowak-Reppel K; Himmel H; Mumberg D; von Nussbaum F; Nising CF; Bauser M; Haegebarth A
J Med Chem; 2019 Jan; 62(2):928-940. PubMed ID: 30563338
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Myers SM; Miller DC; Molyneux L; Arasta M; Bawn RH; Blackburn TJ; Cook SJ; Edwards N; Endicott JA; Golding BT; Griffin RJ; Hammonds T; Hardcastle IR; Harnor SJ; Heptinstall AB; Lochhead PA; Martin MP; Martin NC; Newell DR; Owen PJ; Pang LC; Reuillon T; Rigoreau LJM; Thomas HD; Tucker JA; Wang LZ; Wong AC; Noble MEM; Wedge SR; Cano C
Eur J Med Chem; 2019 Sep; 178():530-543. PubMed ID: 31212132
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel target site for ATP-independent ERK2 inhibitors.
Yoshida M; Nagao H; Sugiyama H; Sawa M; Kinoshita T
Biochem Biophys Res Commun; 2022 Feb; 593():73-78. PubMed ID: 35063772
[TBL] [Abstract][Full Text] [Related]
12. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
[TBL] [Abstract][Full Text] [Related]
13. ERK5: structure, regulation and function.
Nithianandarajah-Jones GN; Wilm B; Goldring CE; Müller J; Cross MJ
Cell Signal; 2012 Nov; 24(11):2187-96. PubMed ID: 22800864
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).
MacKerell AD; Jo S; Lakkaraju SK; Lind C; Yu W
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129519. PubMed ID: 31911242
[TBL] [Abstract][Full Text] [Related]
15. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
[TBL] [Abstract][Full Text] [Related]
16. ERK5 kinase activity is dispensable for cellular immune response and proliferation.
Lin EC; Amantea CM; Nomanbhoy TK; Weissig H; Ishiyama J; Hu Y; Sidique S; Li B; Kozarich JW; Rosenblum JS
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11865-11870. PubMed ID: 27679845
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
[TBL] [Abstract][Full Text] [Related]
18. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.
Brear P; Ball D; Stott K; D'Arcy S; Hyvönen M
J Med Chem; 2020 Nov; 63(21):12786-12798. PubMed ID: 33119282
[TBL] [Abstract][Full Text] [Related]
19. MAP Kinase-Mediated Activation of RSK1 and MK2 Substrate Kinases.
Sok P; Gógl G; Kumar GS; Alexa A; Singh N; Kirsch K; Sebő A; Drahos L; Gáspári Z; Peti W; Reményi A
Structure; 2020 Oct; 28(10):1101-1113.e5. PubMed ID: 32649858
[TBL] [Abstract][Full Text] [Related]
20. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
